Wish list (0)CATO News
CATO CoA Upgrade：Professional Information at a Glance
CATO has upgraded the template for our Certificate of Analysis (CoA). The new certificate is now officially in use.
CATO|CATO|2025-09-12 16:18:37Now Available | CATO Acyclovir EP Impurity R – Empowering Antiviral Drug Quality Control
To support quality research and registration submissions, CATO's in-house developed Impurity R reference standard features high purity and high stability, complete with comprehensive Certificate of Analysis (COA), making it widely applicable for process optimization, method development, registration dossier preparation, and various other application requirements.
CATO|CATO|2025-08-25 14:42:20FDA Adds 12 High-Risk Nitrosamine Impurities, Spotlighting Meglumine-Related NDSRIs
Recently, the U.S. FDA updated its Nitrosamine Impurities Acceptable Intake Limits database, adding 12 new high-risk nitrosamine impurities. Among them, meglumine-related nitrosamine drug substance-related impurities (NDSRIs) have emerged as a major pharmaceutical safety concern, involving more than ten commonly used drugs such as delafloxacin meglumine, iopamidol meglumine, and gadodiamide meglumine.
CATO|CATO|2025-08-11 15:46:08CATO Contributes to the Release of National Standard for Determining Isotopic Abundance in Deuterated Reagents
April 25, 2025 – Guangzhou, China — The State Administration for Market Regulation (SAMR) and the Standardization Administration of China (SAC) have officially released the national standard GB/T 45548-2025 Determination of Isotopic Abundance in Deuterated Reagents—Nuclear Magnetic Resonance (NMR) Spectroscopy.
CATO|CATO|2025-08-11 14:46:50Join us at CPHI China 2025 !
I am writing to invite to meet you in China CPHI on June 24-26, 2025, here is our Booth: # Hall E2G36. Please let me know your preferred meeting time, if you are there.
CATO|CATO|2025-08-04 11:14:55CATO’s New Cosmetic Active Ingredient Series
As skincare formulation becomes more sophisticated, functional active ingredients are now central to product innovation and differentiation. For too long, the high-end cosmetic actives market has been dominated by a handful of global suppliers—resulting in high costs, long lead times, and limited sourcing flexibility for brands worldwide. To meet the growing demand for reliable, high-performance ingredients, CATO introduces its new Cosmetic Active Ingredient Series, featuring a diverse portfolio covering:
CATO|CATO|2025-08-04 11:05:15Notice on Packaging Change of CATO Products
Announcement on the Packaging Upgrade of CATO Reference Standards
CATO|CATO|2025-07-28 18:25:22REACH Annex XVII Adds New Restrictions on DMAC and NEP
On June 3, 2025, the European Union officially published Commission Regulation (EU) 2025/1090 in its Official Journal, introducing significant amendments to REACH Regulation Annex XVII by adding Articles 80 and 81. Two important industrial solvents—N,N-dimethylacetamide (DMAC) and 1-ethylpyrrolidin-2-one (NEP)—have been formally included in the restricted substances list.
CATO|CATO|2025-07-28 17:19:01CATO's Azithromycin-D5: Powering Precision Analytics
Azithromycin-D5 is synthesized by selectively replacing five specific hydrogen atoms in the azithromycin molecular structure with deuterium. It retains identical chemical properties while exhibiting distinct mass spectrometric characteristics.
CATO|CATO|2025-07-28 17:16:54Recommended Major Nitrosamine Impurities : N-Nitroso Finerenone
In recent years, drug safety issues have received significant attention. Among these, nitrosamine impurities have become a "Sword of Damocles" hanging over pharmaceutical companies. On March 28, 2025, the FDA updated its "Nitrosamine Impurities Acceptable Intake Limits" database. This update primarily added and adjusted acceptable intake limits for multiple nitrosamine impurities and expanded the substance categories determined by the prediction-based carcinogenic potency classification approach (CPCA), further strengthening drug safety regulations.
CATO|CATO|2025-07-28 17:09:52
